Table 1.
Clinical characteristics of patients at enrollment
| AOSD (n = 62) | |||
|---|---|---|---|
| Active (n = 41) | Inactive (n = 21) | HC (n = 50) | |
| Age, years | 43.4 ± 14.1 | 37.5 ± 14.2 | 38.6 ± 11.7 |
| Sex, F/M | 31/10 | 15/6 | 37/13 |
| Duration, months | 2.4 ± 2.7 | 13.7 ± 13.0 | |
| Clinical features | |||
| Fever | 38 (92.7) | 0 | |
| Sore throat | 30 (73.2) | 0 | |
| Skin rash | 32 (78.0) | 2 (9.5) | |
| Lymphadenopathy | 30 (73.2) | 2 (9.5) | |
| Splenomegaly | 15 (36.6) | 0 | |
| Hepatomegaly | 1 (2.4) | 0 | |
| Pericarditis | 8 (19.5) | 0 | |
| Pleuritis | 10 (24.4) | 0 | |
| Myalgia | 14 (34.1) | 0 | |
| Arthralgia | 37 (90.2) | 0 | |
| Arthritis | 17 (41.5) | 1 (4.8) | |
| Systemic score | 6.9 ± 2.0 | 0.2 ± 0.5 | |
| Laboratory markers | |||
| Hemoglobin, g/L | 110.2 ± 25.8 | 130.0 ± 16.5 | |
| Leukocytes, 109/L | 17.0 ± 5.5 | 8.1 ± 2.5 | |
| Platelets, 109/L | 285.7 ± 119.6 | 248.9 ± 74.9 | |
| ESR, mm/h | 73.2 ± 27.1 | 17.0 ± 27.9 | |
| CRP, mg/L | 91.5 ± 54.8 | 13.5 ± 16.6 | |
| ALT, U/L | 63.1 ± 58.9 | 27.1 ± 12.0 | |
| AST, U/L | 49.1 ± 20.1 | 31.1 ± 10.3 | |
| Ferritin, ng/ml | 9665.2 ± 4692.7 | 181.8 ± 162.6 | |
| ANA positivity | 6 (14.6) | 1 (4.8) | |
| RF positivity | 2 (4.9) | 0 | |
| Treatments | |||
| Steroid- and sDMARD-naïve | 41 (100) | 2a (9.5) | |
| Low-dose steroid monotherapy | 0 | 0 | |
| High-dose steroid monotherapy | 0 | 0 | |
| sDMARD(s) | 0 | 6 (28.6) | |
| Combination therapy, steroids + sDMARD(s) | 0 | 13 (61.9) | |
Abbreviations: AOSD Adult-onset Still’s disease, HC Healthy control, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, AST Aspartate transaminase, ALT Alanine transaminase, ANA Antinuclear antibody, RF Rheumatoid factor, sDMARD Synthetic disease-modifying antirheumatic drug
Low dose of steroids was defined as ≤ 0.5 mg/kg/day of prednisone; high dose of steroids was defined as > 0.5 mg/kg/day of prednisone
All values are presented as number (percent) or mean ± SD
aDrug withdrawal